The board of directors of SSY Group Limited announced that the Group's Lidocaine hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Lidocaine hydro chloride is a local anesthesia and antiarrhythmic drug. It is mainly used in infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.33 HKD | +0.46% |
|
-0.23% | -12.35% |
Jul. 05 | Chinese Regulator Approves SSY Group's Several Drugs for Production, Registration | MT |
Jul. 05 | SSY Group Limited Announces Update on Product Development | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.35% | 1.65B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Provides Update on Product Development